American Urogynecologic Society
Medical professional community for individuals and companies in the field of urogynecology
Based in DC
AI Overview
With $380K in lobbying spend across 28 quarterly filings, American Urogynecologic Society is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2018 to 2024.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $40K |
| 2019 | $40K |
| 2020 | $50K |
| 2021 | $40K |
| 2022 | $60K |
| 2023 | $80K |
| 2024 | $70K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that American Urogynecologic Society disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, Health Issues
-- H.R. 1892 - Continuing Resolution: Changes to the Medicare Access and CHIP Reauthorization Act of 2016 regarding CMS flexibility for cost measures, penalties, Part B drugs, and PTAC
-- H.R. 3358 / S. 1771 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; H.R. 1892 - Continuing Resolution; H.R. 1625 - Vehicle for Conso
-- House Subcommittee Draft / S. 3158: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019: Federal research funding for pelvic floor disorder
-- H.R. 6740 / S. 3158 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019; H.R.6157 - Department of Defense and Labor, Health and Human Ser
-- CY 2019 Proposed Medicare Fee Schedule - Proposal regarding office visit documentation and payments; congressional letters to Centers for Medicare and Medicaid Services.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.